JPRN-jRCT2080221159未知2 期
Phase 2/3 Study of SK-0503 in Patients with Macular Edema Following Branch Retinal Vein Occlusion
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •(1) Patients with macular edema that developed in the study eye from 52 weeks (364 days) to 6 weeks (42 days) prior to qualification/baseline visit
- •(2) Patients whose best corrected visual acuity is between 34 and 68 letters inclusive in the study eye as measured by the ETDRS method
- •(3) Patients with a central macular retinal thickness of at least 350 µm in the study eye as measured by optical coherence tomography
排除标准
- •(1) Patients whose BCVA score of less than 34 letters measured by the ETDRS method at qualification/baseline visit
- •(2) Patients with a history of steroid-induced intraocular pressure elevation
- •(3) Patients with diabetic retinopathy
- •(4) Patients with cancer, serious liver disease, serious renal disease, or serious heart disease
研究者
相似试验
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-DEAbbVie Deutschland GmbH & Co.KG90
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EUCTR2017-003171-64-NLAbbVie Deutschland GmbH & Co.KG40
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-GBAbbVie Deutschland GmbH & Co.KG90
尚未招募
Unknown
Macular Atrophy Clinical StudyJPRN-UMIN000052309Keio University School of Medicine300
已完成
不适用
Ocular surface evaluation in ocular hypertension or inicial glaucoma patients treated with drops.Ocular hypertension or Open angle Glaucoma with no previous treatment.H40.0H40.1RBR-7mmp6kniversidade Federal de São Paulo